Clear All
11398 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50090-7480-02 50090-7480 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Dec 20, 2024 In Use
70518-4243-00 70518-4243 PREDNISONE PREDNISONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec 20, 2024 In Use
50090-7481-00 50090-7481 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Dec 20, 2024 In Use
50090-7480-00 50090-7480 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Dec 20, 2024 In Use
70518-4145-02 70518-4145 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 20, 2024 In Use
70518-4245-00 70518-4245 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 20, 2024 In Use
70436-0119-80 70436-0119 Leucovorin calcium Leucovorin Calcium 350.0 mg/1 Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Dec 27, 2024 In Use
80425-0473-01 80425-0473 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 29, 2024 In Use
80425-0469-01 80425-0469 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 29, 2024 In Use
00009-0112-05 00009-0112 Irinotecan hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec 30, 2024 In Use
00009-7529-10 00009-7529 Irinotecan Hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec 30, 2024 In Use
83831-0112-01 83831-0112 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
81927-0105-01 81927-0105 Thiotepa TEPYLUTE 10.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intravenous Jan 1, 2025 In Use
83831-0131-01 83831-0131 Pemetrexed AXTLE 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
83831-0132-01 83831-0132 Pemetrexed AXTLE 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
69448-0015-05 69448-0015 Trastuzumab-strf HERCESSI 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan 1, 2025 In Use
82143-0002-01 82143-0002 Bevacizumab-tnjn Avzivi 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan 1, 2025 In Use
83831-0111-01 83831-0111 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
82143-0001-01 82143-0001 Bevacizumab Avzivi 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan 1, 2025 In Use
58181-4102-05 58181-4102 Cyclophosphamide Cyclophosphamide 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Jan 1, 2025 In Use
58181-4115-00 58181-4115 Cyclophosphamide Cyclophosphamide 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Jan 1, 2025 In Use
69448-0016-11 69448-0016 Trastuzumab-strf HERCESSI 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan 1, 2025 In Use
72603-0329-01 72603-0329 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Jan 1, 2025 In Use
52658-7777-01 52658-7777 Denileukin diftitox-cxdl LYMPHIR 300.0 ug/2mL Immunotherapy Cytokine Interleukin-2 Intravenous Jan 1, 2025 In Use
00003-6120-01 00003-6120 Nivolumab and hyaluronidase-nvhy OPDIVO QVANTIG 2000.0 U/mL, 120.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Subcutaneous Jan 2, 2025 In Use

Found 11398 results — Export these results